---
title: "SINOTHERAPEUTICS subsidiary Xuantai Pharmaceutical has passed the EU GMP certification"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248916235.md"
description: "SINOTHERAPEUTICS's wholly-owned subsidiary, Jiangsu SINOTHERAPEUTICS Pharmaceutical Co., Ltd., recently received GMP certification from the European Medicines Agency (EMA). This is another significant achievement following its certifications from multiple national drug regulatory authorities, including China's NMPA, the U.S. FDA, Japan's PMDA, and Saudi Arabia's SFDA. It signifies that the company's quality system is aligned with international standards, helping to expand overseas markets, enhance market competitiveness, and support the company in providing R&D and production services to global pharmaceutical and biotechnology companies"
datetime: "2025-07-17T07:44:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248916235.md)
  - [en](https://longbridge.com/en/news/248916235.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248916235.md)
---

# SINOTHERAPEUTICS subsidiary Xuantai Pharmaceutical has passed the EU GMP certification

According to the Zhitong Finance APP, SINOTHERAPEUTICS (688247.SH) announced that its wholly-owned subsidiary Jiangsu SINOTHERAPEUTICS Co., Ltd. (referred to as "SINOTHERAPEUTICS") has received the "Drug GMP Certificate" issued by the National Public Health and Pharmacy Center of Hungary in accordance with the relevant regulations of the European Medicines Agency (EMA).

The GMP certification obtained by SINOTHERAPEUTICS through the EU EMA is another good certification record following its certifications from various regulatory authorities such as NMPA (National Medical Products Administration of China), FDA (U.S. Food and Drug Administration), PMDA (Pharmaceuticals and Medical Devices Agency of Japan), and SFDA (Saudi Food and Drug Authority). This signifies that the company's quality system consistently aligns with international standards. This will strongly promote the expansion of the company's products in overseas markets and enhance the company's market competitiveness; at the same time, it will continuously support the company in providing one-stop formulation R&D and production services to global pharmaceutical and biotechnology companies, providing strong support for the company's recognition by clients

### Related Stocks

- [688247.CN](https://longbridge.com/en/quote/688247.CN.md)

## Related News & Research

- [IPO Winners & Losers Podcast: Cerebras, SpaceX, and the AI Takeover](https://longbridge.com/en/news/286957979.md)
- [Former Spanish Prime Minister Zapatero is under investigation linked to airline bailout](https://longbridge.com/en/news/287039440.md)
- [JD Vance Says Hunter Biden Is 'Welcome' To Seek Payout From DOJ's $1.8 Billion 'Slush Funds'—'The President...Has Pardoned..'](https://longbridge.com/en/news/287054505.md)
- [Assessing BlueNord (OB:BNOR) Valuation After Its US$400 Million Refinancing Deal](https://longbridge.com/en/news/287098111.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)